Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Para-Methoxyamphetamine SCHEMBL895775 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL394418 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL7253563 | 0.98 | SLC6A4 (0.96) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL10975159 | 0.98 | SLC6A4 (0.96) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL9468376 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL9468512 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL6540600 | 0.86 | SLC6A4 (0.74) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL7528408 | 0.84 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL656814 | 0.84 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL10774940 | 0.84 | SLC6A4 (0.73) | SLC6A4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1012 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250130211-A1 | METHOD OF SCREENING NEW PSYCHOACTIVE SUBSTANCE AND PLATFORM THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-04-24 | — | — | US | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-117904097-A | Self-assembled protein scaffold co-immobilized enzyme and application thereof | 浙江工业大学 | 2024-04-19 | — | — | CN | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| CN-115656376-A | Method for separating and detecting formoterol related substances | 苏州易合医药有限公司 | 2023-01-31 | — | — | CN | claimed |
| EP-4061359-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Turtle Bear Holdings, LLC (US) | 2022-09-28 | — | — | EP | claimed |
| EP-1704140-A1 | SYNTHESIS OF OPTICALLY PURE (R)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULPHONAMIDE | LEK Pharmaceuticals D.D. (SI) | 2006-09-27 | — | — | EP | claimed |
| US-20060148046-A1 | Enzymatic process for the preparation of an intermediate compound and use thereof for the synthesis of tamsulosin hydrochloride | QUIMICA SINTETICA, S.A. | 2006-07-06 | — | — | US | claimed |
| WO-2006070285-A2 | ENZYMATIC PREPARATION OF AN INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF TAMSULOSIN | QUIMICA SINTETICA, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| WO-2005063701-A1 | SYNTHESIS OF OPTICALLY PURE (R)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULPHONAMIDE | LEK PHARMACEUTICALS D.D. (CH) | 2005-07-14 | — | — | WO | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| EP-0848065-B1 | Method for improving optical purity of an amine compound | SUMITOMO CHEMICAL CO (JP) | 2003-04-02 | — | — | EP | claimed |
| US-20020013372-A1 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| EP-1134290-A2 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| US-5965432-A | PREFERENTIALLY METABOLIZING (S) ENANTOMORPH OF MIXTURE USING CULTURE OF ARTHROBACTER, CULTURE LIQUID, GEL IMMOBILIZED CELLS, FREEZE-DRIED OR ACETONE-DRIED CELLS, GROUND OR AUTODIGESTED CELLS, ULTRASONIC TREATED OR EXTRACTED CELLS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | claimed |
| EP-0848065-A2 | Method for improving optical purity of an amine compound | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-06-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | SLC6A4 2641/4885CYP1A2 1124/4885CYP2D6 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.